Izotropic Nominated for Best New Radiology Device Award
VANCOUVER, BC - TheNewswire -September 9, 2021 -Izotropic Corporation (“Izotropic” or the “Company”) (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3) a Company commercializing a dedicated Breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, announced today that it received a semifinalist nomination forAuntMinnie.com's 2021 award campaign to recognize the best and brightest in medical imaging.
Auntminnie.com, a leading radiology news website, has recognized Izotropic’s IzoView Breast CT System in the Best New Radiology Device category. The Company congratulates all other nominees, as it is an honor to be considered for this award.
Izotropic thanks all of those who have worked on and continue to work on IzoView Breast CT and attributes this nomination to everyone’s passion and commitment to improving the outcomes of women’s breast cancer.
Izotropic is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic’s initial clinical study, scheduled to begin in Q2 2022, intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
IzoView (currently in development) produces high resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10 second scan acquires approximately 500 images without painful breast compression or continual technician breast handling, providing a more comfortable patient experience with low radiation dose levels.
In addition to improved detection capabilities, Izotropic anticipates IzoView’s higher resolution 3D images could provide more accurate margin analysis (viewing edges of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (the imaging ability to differentiate between internal breast structures). More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
ON BEHALF OF THE COMPANY
Dr. John McGraw, CEO
For investor relations inquiries, contact: James Berard, Investor Relations Manager
Email: jberard@izocorp.com Cell: 778-228-2314 Toll Free: 1-833-IZOCORP ext.1